ArticleMolecular cancer therapeutics2017
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity.The Journal of pharmacology and experimental therapeutics · 2025Article
- Younger Age Is Associated with Favorable Outcomes in Adult Dogs with Hemangiosarcoma Receiving Adjuvant Doxorubicin Chemotherapy: Results from the PRO-DOX Study.Research square · 2025Article
- Osteosarcoma: A comprehensive review of model systems and experimental therapies.Medical research archives · 2024Article
- Article
- Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers.Annual review of biomedical data science · 2024Review
- Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.Biomedicines · 2024Review
- Review
- Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.Journal of translational medicine · 2022Review
- Increased risk of cancer in dogs and humans: a consequence of recent extension of lifespan beyond evolutionarily-determined limitations?Aging and cancer · 2022Article
- Review
- Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma.PloS one · 2022Article
- Immunotoxins: From Design to Clinical Application.Biomolecules · 2021Article
- Application of deep learning to understand resilience to Alzheimer's disease pathology.Brain pathology (Zurich, Switzerland) · 2021Article
- The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.Cancers · 2021Review
- Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions.Molecular cancer research : MCR · 2021Article
- Retrospective evaluation of thrombocytopenia and tumor stage as prognostic indicators in dogs with splenic hemangiosarcoma.Journal of the American Veterinary Medical Association · 2021Article
- Impact of repeated cycles of EGF bispecific angiotoxin (eBAT) administered at a reduced interval from doxorubicin chemotherapy in dogs with splenic haemangiosarcoma.Veterinary and comparative oncology · 2020Article
- The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study.Scientific reports · 2020Article
- Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors.Biomolecules · 2020Review
- Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.Molecular cancer research : MCR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
Antonella BorgattiAnimal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, Minnesota. borgatti@umn.edu.
Joseph S KoopmeinersMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Aaron L SarverMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Amber L WinterClinical Investigation Center, College of Veterinary Medicine, St. Paul, Minnesota.
Kathleen StuebnerClinical Investigation Center, College of Veterinary Medicine, St. Paul, Minnesota.
Deborah TodhunterMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Anthony E RizzardiDepartment of Pathology, University of Washington School of Medicine, Seattle, Washington.
Jonathan C HenriksenDepartment of Pathology, University of Washington School of Medicine, Seattle, Washington.
Stephen SchmechelDepartment of Pathology, University of Washington School of Medicine, Seattle, Washington.
Colleen L ForsterBioNet Histology Research Laboratory, Academic Health Center, University of Minnesota, Minneapolis, Minnesota.
Jong-Hyuk KimAnimal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, Minnesota.
Jerry FroelichDepartment of Radiology, School of Medicine, University of Minnesota, Minneapolis, Minnesota.
Jillian WalzAnimal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, Minnesota.
Michael S HensonAnimal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, Minnesota.
Matthew BreenDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, and Center for Comparative Medicine and Translational Research, North Carolina State University, Raleigh, North Carolina.
Kerstin Lindblad-TohBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Felix OhDepartment of Radiation Oncology, School of Medicine, University of Minnesota, Minneapolis, Minnesota.
Kristy PilbeamDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Jaime F ModianoAnimal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, Minnesota.
Daniel A ValleraAnimal Cancer Care and Research (ACCR) Program, University of Minnesota, St. Paul, Minnesota.
University of Minnesota · USUniversity of Washington · USBioClinica (United States) · USBroad Institute · USNorth Carolina State University · US
Funding
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4MUniversity of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0MIMMUNOTOXINS IN HUMAN BONE MARROW TRANSPLANTATIONR01CA036725 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI VALLERA, DANIEL A · 1985 to 2015
$3.3MPreclinical evaluation and clinical translation of novel bispecific toxins that tK01OD017242 · OD · UNIVERSITY OF MINNESOTA · PI BORGATTI, ANTONELLA M · 2014 to 2018
$739kBioinformatics approaches to solve the "Missing Driver" problem in solid tumorsR50CA211249 · NCI · UNIVERSITY OF MINNESOTA · PI SARVER, AARON L · 2016 to 2020
$565kNCATS NIH HHS UL1 TR000114NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA036725NCI NIH HHS R50 CA211249NIH HHS K01 OD017242
Abstract
Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized
Indexed as
Molecular Targeted TherapyADP Ribose TransferasesAnimalsBacterial ToxinsCell Line, TumorDisease Models, AnimalDogsDoxorubicinEpidermal Growth FactorErbB ReceptorsExotoxinsHemangiosarcomaHumansMiceNeoplasm StagingPseudomonas aeruginosa Exotoxin AADP Ribose TransferasesBacterial ToxinsDoxorubicinEGFR protein, humanEpidermal Growth FactorErbB ReceptorsExotoxinsPseudomonas aeruginosa Exotoxin AReceptors, Urokinase Plasminogen ActivatorUrokinase-Type Plasminogen ActivatorVirulence Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.